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Abstract 
 
Familial hypercholesterolemia is an autosomal dominant disorder characterized by el-
evated levels of low density lipoprotein (LDL) carrying cholesterol in the blood. FH 
is mainly caused by mutations in the gene encoding the low density lipoprotein recep-
tor (LDLR) which causes altered lipid metabolism. LDLR is synthesized and initially 
modified by glycosylation in the endoplasmic reticulum (ER) and transferred to the 
plasma membrane by Golgi to carry out LDL clearance from the blood stream. Defec-
tive LDLR can therefore lead to increased levels of LDL in the blood which may lead 
to atherosclerosis and premature coronary artery diseases. 
For the past few years, cardiovascular diseases have been found to be the leading cause 
of morbidity and mortality in UAE. In this study, the pathogenesis of a group of seven 
missense LDLR variants (p. Cys167Phe), (p. Asp178Asn), (p. Glu277Lys), (p. 
Gly314Arg), (p. His327Tyr), (p. Met652Thr) and (p. Arg814Gln) were evaluated and 
identified in Emirati patients with suspected familial hypercholesterolemia (FH). The 
aim of this project was to generate the identified missense LDLR variants in mamma-
lian expression vector, establish their subcellular localization using confocal micros-
copy and evaluate their glycosylation status. It was found that several of these variants 
resulted in an apparent partial retention of the LDLR mutants in the ER and hence their 
possible failure to pass the ER quality control system.  Several of the studied missense 
mutants will be further studied in the future to investigate their exact pathogenicity 
mechanism and cellular impact on the ER and endoplasmic reticulum associated pro-
tein degradation (ERAD).  
Keywords: Familial Hypercholesterolemia (FH), Low Density Lipoprotein Receptor 
(LDLR), Premature Coronary Artery Disease (CAD), Endoplasmic Reticulum 
Associated Protein Degradation (ERAD), Endoplasmic Reticulum (ER). 
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 )cibarA ni( tcartsbA dna eltiT
 
 العربية تالامارا في العائلي الدم لكولسترو فرط تسبب التي للمتغيرات الخليوية الأسس
 المتحدة
  صالملخ
ين الدم العائلي هو اضطراب وراثي سائد يتميز بمستويات مرتفعة من البروت لكولسترو طفر
ائلي بشكل لسترول الدم العوفي الدم ينتج فرط ك لالكولسترويحمل  الذيالدهني المنخفض الكثافة 
يير يتسبب في تغ والذيالبروتين الدهني المنخفض الكثافة  مستقبلات أساسي عن طفرة في جين
ندبلوزماية يتم تصنيع مستقبلات البروتين الدهني المنخفض في الشبكة الأ لدهونالتمثيل الغذائي ل
يمكن  البروتين الدهني المنخفض. لإزالةنقله الى غشاء البلازما عن طريق جهاز جولجي  ويتم
الدهني  دهني المنخفض المعطلة الى زيادة في مستويات البروتينتؤدي مستقبلات البروتين الأن 
 ايين. أن يؤدي الى أمراض الشرايين التاجية المبكرة مثل تصلب الشر ويمكنالمنخفض في الدم 
الرئيسي  الدموية باعتبارها السبب والأوعيةخلال العاميين الماضيين، تم اكتشاف أمراض القلب 
 .p( طفراتالفي هذه الدراسة تم تحديد قائمة من دولة الامارات العربية المتحدة.   للوفيات في 
                         .p( ,)ryT723siH .p( ,)grA413ylG .p( ,)syL772ulG .p( ,)nsA871psA .p( ,)ehP761syC
ف مراتيين. الهدإلسترول الدم من مرضى ولفرط كة المتسبب )nlG418grA .p( و )rhT256teM .p(
ية. داخل الخل وحالتهاموقعها  ودراسةمن هذه الأطروحة هو تصنيع هذه اللائحة من الطفرات 
وتأثيرها  سيتم إجراء المزيد من الدراسات على الطفرات في المستقبل للتحقق من قدرتها المرضية
  .البروتينات المرتبطة بالشبكة الإندوبلازمية
نخفض لسترول الدم العائلي، مستقبلات البروتين الدهني الموك فرط مفاهيم البحث الرئيسية:
، الشبكة نة بتدهور البروتيطكر، الشبكة الاندوبلازمية المرتبالكثافة، مرض شريان التاجي المب
  الاندوبلازمية.
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Chapter 1: Introduction 
 
1.1 Overview 
Lipids are essential components that make up major constituents of the struc-
ture of the cell membrane as well as other cellular endomembranes. The plasma 
membrane is an organelle that functions as a permeability barrier between the inter-
nal environment of the cell and the external environment (Ikonen, 2008). Also, it is 
responsible for the diffusion of ions and solutes in and out of the cell and it maintains 
electrical potentials (Ikonen, 2008). Furthermore, the cell membrane is a major site 
for cellular signaling and communication. An important lipid ingredient that consti-
tutes the mammalian plasma membrane is cholesterol.  
1.2 Cholesterol: structure, biosynthesis and homeostasis 
Cholesterol is one of the most important contents of the phospholipid bilayer 
of the cell membrane as it makes up 20% to 25% of the lipid molecules such as glyco-
lipids, sphingomyelin and a variety of phospholipids (Ikonen, 2008). A major function 
of cholesterol is to provide fluidity to the cell membrane and creates a semi permeable 
barrier between cellular organelles (Ikonen, 2008). In addition, it has an unequal dis-
tribution across cellular membranes giving the membrane a mosaic appearance 
(Ikonen, 2008). Furthermore, cholesterol plays an important role in membrane traf-
ficking and mediates numerous transmembrane signaling processes (Ikonen, 2008). 
Cholesterol is a hydrophobic molecular and with a unique structural composition (Fig-
ure 1.1) constituting a four hydrocarbon ring called “steroid nucleus” as well as long 
hydrocarbon tail made up of eight hydrocarbon chain (Soliman, 2018). 
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Figure 1.1: Schematic diagram of the structural composition of cholesterol. Adapted 
from PubChem Database (2020).  
 
The structural composition of cholesterol allows an increase in its interaction 
and cohesion with neighboring lipid molecules (Ikonen, 2008). The “steroid nucleus” 
acts as a precursor for the synthesis of several steroid hormones such as Testosterone, 
Progesterone, Estrogen and Vitamin D. In addition, steroids and bile acids are metab-
olites of cholesterol that perform as solubilizers and signal transducers of other lipids. 
In humans, cholesterol is either synthesized endogenously by tissues and cells or pro-
vided exogenously from diet (Ikonen, 2008). Endogenously, cholesterol is de novo 
synthesized mainly by the liver, intestine and reproductive organs through the meva-
lonate pathway (Soliman, 2018).  
The improper composition of plasma membranes can lead to serious conse-
quences which can result in altered cellular functions such as defective cellular signal-
ing and protein trafficking (Ikonen, 2008). The overall cholesterol: protein ratio is cor-
related and highly vary depending on cell type and density (Ikonen, 2008). Accumu-
lation and buildup of cholesterol in the arteries can the narrowing down of the arteries 
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and eventually lead to coronary artery diseases such as atherosclerosis seen in Figure 
1.2.  
 
 
 
Figure 1.2: Comparison between a normal artery and an atherosclerotic artery. 
Adapted from Topfer & Spry (2016).  
 
However, cholesterol levels abnormalities can also cause defective cholesterol 
storage monogenic disorders such as Familial Hypercholesterolemia (FH) and lysoso-
mal cholesterol–sphingolipid storage diseases (Ikonen, 2008). In addition, cholesterol 
has been shown to be involved in common conditions such as diabetes, cancer and 
dementias (Ikonen, 2008). Cholesterol has an interesting physiological structure and 
its importance in vertebrates and has fueled so many molecular and cellular research 
activities in vitro and in vivo. Mostly, cell lines such as enterocytes, hepatocytes and 
central nervous system cells were used to study cholesterol but animal models such as 
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mice remain more ideal, reliable and convenient to conduct research on cholesterol 
homeostasis but not in studying atherosclerosis as mice contain cholesterol in circulat-
ing HDL (high density lipoprotein) which contributes to making mice resistant to ath-
erosclerosis (Ikonen, 2008). As already mentioned, in humans circulating cholesterol 
is either derived exogenously through a diet or endogenously through de novo synthe-
sis via the mevalonate pathway (Figure 1.3). Moreover, there is a balance mechanism 
through which the cholesterol levels in the blood are regulated and homeostasis main-
tained (Soliman, 2018). For example, when there are high levels of exogenous dietary 
cholesterol, the de novo synthesis of cholesterol in the body is decreased (Soliman, 
2018). De novo synthesis of cholesterol is performed by nucleated cells through the 
mevalonate pathway starting from acetyl CoA (Ikonen, 2008) as shown in Figure 1.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Schematic diagram representing the biosynthesis of cholesterol which in-
volves two pathways: Bloch pathway and Kandutsch- Russell pathway mainly start-
ing with acetate and ending with cholesterol. Modified and adopted from Singh et al. 
(2013).  
5 
 
 
 
 
The first step of cholesterol biosynthesis demands the availability of O2 and 
operates under aerobic conditions by converting Lanosterol which is the first interme-
diate in the mevalonate pathway (Ikonen, 2008). The rate-limiting enzyme 3-hydroxy-
3-methyl-glutaryl-coenzyme A reductase (HMG-CoAR) catalyzes the reduction of 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) to mevalonate (Ikonen, 2008). 
Both this reaction and sequential other reactions are catalyzed by integral ER mem-
brane proteins (Ikonen, 2008). It is worth mentioning that the main used cholesterol -
lowering drugs such as statins do so by inhibiting the 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase (HMG-CoAR) enzyme. 
In addition to cholesterol synthesis, triglycerides are continuously synthesized 
by the liver using carbohydrates and free fatty acids as substrates. After the synthesis 
of triglycerides, they are released by the liver and they reside in the core of the very 
low density lipoprotein (VLDL) (Niu & Evans, 2011). VLDL undergoes structural 
modifications involving the addition of apo protein B-48 along with apo proteins C 
and E. Afterwards, lipoprotein lipase breaks down core triglycerides and converts 
VLDL into intermediate-density lipoproteins (IDL) or remnant VLDL and release of 
free fatty acids (Niu & Evans, 2011). During their circulation, some of the remnant 
VLDL or IDL are eliminated by strongly binding to hepatocytes and the remaining 
remnant VLDL or IDL are processed into LDL by substituting triglycerides into cho-
lesterol esters, keeping the apo protein B and removing the other apo proteins shown 
in Figure 1.4 (Niu & Evans, 2011).  
On the other hand, dietary or exogenous cholesterol is absorbed by the gut and 
transferred to the liver and then secreted into the blood stream and the lymph system 
(Ikonen, 2008). Enterocytes and hepatocytes take up cholesterol and repackage it into 
a more transportable form of lipoproteins that vary in composition and are modified 
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through the circulation in the body (Ikonen, 2008). Basically, dietary cholesterol is 
first absorbed and packaged into chylomicrons with triglycerides by the enterocytes of 
the small intestine (Ikonen, 2008). Chylomicrons are transformed into chylomicron 
remnants through the hydrolysis of triglycerides and coupling of new apoproteins such 
as apoE (Ikonen, 2008). Hepatocytes in the liver absorb chylomicron remnants and 
produce lipids packaged into very low density lipoproteins (VLDL) where it gets me-
tabolized into intermediate density lipoprotein (IDL) and is eventually metabolized 
into low density lipoprotein (LDL) as shown in Figure 1.4 (Ikonen, 2008).  
 
 
 
Figure 1.4: Schematic representation of the exogenous and endogenous pathways of 
cholesterol. Adapted from Karam et al. (2017).  
 
Lipoproteins are classified into different classes such as chylomicrons, very 
low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), high density 
lipoprotein (HDL) and low density lipoprotein (LDL) (Sima et al., 2018). The common 
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general structural characteristics of these lipoproteins is a spherical shape made up of 
lipid cores containing different portions of cholesteryl esters, triglycerides and choles-
terol as well as a coat of phospholipids and different Apo lipoproteins (Soliman, 2018). 
However, the composition and quantities of triglycerides, Apo proteins and cholesterol 
esters may vary from particle to particle due to a cascade of interactions through their 
circulation involving several enzymes such as hepatic triglyceride lipase (HTGL), lec-
ithin-cholesterol acyltransferase (LCAT), lipoprotein lipase (LPL), and cholesteryl es-
ter transfer protein (CETP) (Dominiczak & Caslake, 2011). Due to cholesterol’s insol-
ubility, it cannot be circulated freely in the blood stream and thus is packaged into a 
more transportable particles called low density lipoprotein (LDL) where most of the 
cholesterol molecule is esterified into cholesterol esters (Sima et al., 2018). The LDL 
particles are captured by low density lipoprotein receptors (LDLR) on the surface of 
some cell types and the LDL- LDLR complex is engulfed by the cell through a process 
called endocytosis (Go & Mani, 2012). The internalized LDL-LDLR complex is car-
ried into endosomes, hydrolyzed by lysosomes, LDL liberated into the cytoplasm 
while LDLR is recycled back to the surface of the cell membrane (Go & Mani, 2012).  
A defect in the clearance of LDL by LDLR can cause build up and narrowing 
of cholesterol in the arteries causing premature coronary artery diseases such as ather-
osclerosis as illustrated in Figure 1.10 Basically, when LDL levels are elevated in the 
blood, they undergo oxidation resulting in oxidized LDL (Ox-LDL) (Sima et al., 
2018). Consequently, Ox-LDL leads to constant adherence and accumulation to the 
arterial walls and causes continues chronic inflammation (Sima et al., 2018).  
1.3 Lipoproteins: diversity and composition 
The composition and functions of the various cellular lipoproteins and some of 
their protein components are summarized in the following sections: 
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1.3.1 Chylomicrons 
Out of all the mentioned lipoproteins, chylomicrons are the largest in terms of 
their size, the rate at which they are absorbed and the type of fat absorbed (Julve et al., 
2016). Chylomicrons are composed of a lipid core mostly made out of 85-92% of 
monoglycerides and triglycerides, 6-12% of phospholipids, 1-3% of free and esterified 
cholesterol as well as a very small amount of fatty acids (Julve et al., 2016). One of 
the most important ingredients in a chylomicron particle are the apo lipoproteins mak-
ing less than 2% of chylomicrons (Julve et al., 2016). For chylomicrons, apo lipopro-
teins B48 determines a chylomicrons metabolic destiny and plays a crucial role in chy-
lomicrons biosynthesis and production (Julve et al., 2016).   
1.3.2 Very low density lipoprotein (VLDL)  
Very-low-density lipoprotein (VLDL) are mainly composed and enriched with 
triacylglycerol (TAG). VLDL synthesized and secreted by parenchymal liver cells 
(Niu & Evans, 2011). VLDL is one of the five major lipoproteins and is comprised of 
a central core of hydrophobic TAG as well as cholesteryl esters which are coated with 
a hydrophilic monolayer of phospholipids and apolipoprotein B100 (Apo B100)(Niu 
& Evans, 2011). TAG contained in VLDL’s core is made using endogenous fatty acid 
sources that are derived from lipolysis in adipose tissues, hepatic de novo lipogenesis 
and hydrolysis of plasma lipoprotein (Niu & Evans, 2011). Thus, VLDL performs as 
a redistributor of endogenous lipids derived from the liver to cells in peripheral tissues 
(Niu & Evans, 2011). 
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1.3.3 Low density lipoproteins (LDL)   
Out of all the lipoprotein molecules, LDL is considered to be the most harmful 
and dangerous lipoprotein for health (Sima et al., 2018). Lipoproteins are packaged by 
complex Apo lipoprotein molecules that surface cell membranes shown in Figure 1.5 
and interact with particular expressed receptor cell membrane proteins (Sima et al., 
2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Schematic drawing and predication of the structure of low density lipo-
protein (LDL). Adapted and modified from Goldstein et al. (2001).  
 
LDL is a spherical molecule with a diameter of  220 nm built up of a hydrophilic or 
amphipathic monolayer coat of phospholipids and un-esterified cholesterol as well as 
a hydrophobic core made of esterified cholesterol (Mateu et al., 1972). The hydrophilic 
coat of LDL contains a hydrophobic type of apo proteins specifically apo-B which 
facilitates the binding of LDL to LDL receptors. LDL’s predominant role is to deliver 
and provide peripheral cells with cholesterol where needed (Ikonen, 2008). The 
amount of liberated cholesterol from LDL has been set to regulate cholesterol’s home-
ostasis via three mechanisms: first, it reduces the expression of enzyme 3-hydroxy-3 
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methylglutaryl coenzyme A (HMG-CoA) reductase when LDL-C increases in the cell 
which alters intracellular cholesterol synthesis. Secondly, LDL cholesterol can initiate 
the activation of another enzyme which in turn improves the storage of cholesterol in 
the cell. Lastly, high levels of cholesterol stimulate a negative feedback process which 
reduces the generation of LDL receptors (Cox & García-Palmieri, 1990).  
1.3.4 High density lipoprotein (HDL)  
HDL is the tiniest and heaviest lipoproteins out of all five lipoproteins 
(Yetukuri et al., 2010). It is 5-17 nm in size and weighs 1.063-1.210 kg/l (März et al., 
2017). One of the major protein constituents in HDL is apolipoprotein (Apo AI) and 
apolipoprotein (Apo AII) (Yetukuri et al., 2010) (Kosmas et al., 2018). Apo AI makes 
up to 70% of the overall composition of an HDL molecule compared to Apo AII which 
makes up to 20% of an HDL molecule only (Kosmas et al., 2018). In cases where 
cholesterol is in excess, it is transported to the liver by HDL in a pathway referred to 
as reverse cholesterol transport (RCT) (März et al., 2017). Also, LDL plays a role in 
RCT (März et al., 2017). RCT is a process through which cholesterol is transferred 
from peripheral tissues into blood circulation and is finally discarded in feces. HDL 
has the power not to only being a cholesterol acceptor and play “the good cholesterol” 
but also as a cholesterol transporter in RCT pathway as well as sending cholesterol to 
the liver (Ouimet et al., 2019).  
1.3.5 Apo lipoproteins (Apo)   
As previously mentioned, the action of enzymes such as hepatic triglyceride 
lipase (HTGL), lecithin-cholesterol acyltransferase (LCAT), lipoprotein lipase (LPL), 
and cholesteryl ester transfer protein (CETP) are modulated by apo lipoprotein which 
determine a lipoprotein conformation and structure (Dominiczak & Caslake, 2011). 
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The predominant role of apolipoproteins is to regulate the ligand-receptor binding of 
lipoproteins to their designated lipoprotein receptors. Apolipoproteins such as apolipo-
protein E (apoE) and apolipoprotein B100 (apoB100) bind with LDL receptors that 
recognize apoE and apoB100 (Dominiczak & Caslake, 2011). Also, apoE can specifi-
cally bind with another family of LDLR which are the low density related protein re-
ceptors (LRP) (Dominiczak & Caslake, 2011). 
1.3.6 Apolipoprotein B100 (ApoB100)   
ApoB100 has a molecular mass of 555,000 Da and decreases to 513,000 Da 
when it is cleaved at the N terminal end. ApoB100 is made up of 4536 amino acids 
and produced by hepatocytes. A defective apoB100 can lead to impaired ligand- re-
ceptor binding and can lead to a genetic disorder known as familial defective apoB 
(FDB). ApoB can be found in both VLDL and LDL at a ratio of one apoB molecule to 
one lipoprotein molecule (Dominiczak & Caslake, 2011).  
1.3.7 Apolipoprotein B48 (ApoB48)   
ApoB48 is produced by enterocytes and has a molecular mass of 264,000 Da 
and is made up of 2152 amino acids (Dominiczak & Caslake, 2011). ApoB48 and 
apoB100 are synthesized by a single gene but apoB48 is a truncated form of apoB100 
(Dominiczak & Caslake, 2011). At the molecular level, cytidine nucleotide 6666 gets 
deaminated and is transferred a uridine during apoB mRNA editing process which re-
sults in a stop codon (Dominiczak & Caslake, 2011). The stop codon is what makes 
apoB48 (Dominiczak & Caslake, 2011). ApoB48 is inserted into chylomicrons and 
they also remain in chylomicron’s remnants (Dominiczak & Caslake, 2011). A mole-
cule of apoB48 is equal to one molecule of chylomicrons (Dominiczak & Caslake, 
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2011). However, since apoE48 doesn’t have an LDL-receptor binding domain, chylo-
micron remnants are captured by apoE possessing LRP and LDL receptor binding do-
mains (Dominiczak & Caslake, 2011). It has been studied that, particles having sizes 
lesser than 70–80 nm can diffuse through vascular walls (Dominiczak & Caslake, 
2011). Hence, nascent chylomicrons cannot penetrate through vascular walls while 
chylomicron remnants can (Dominiczak & Caslake, 2011). So, chylomicron remnants 
are considered atherogenic since they are rich in cholesteryl esters that are brought up 
through exchange with HDL during chylomicron remnants circulation in the body 
(Dominiczak & Caslake, 2011).  
1.3.8 Apolipoprotein AI (Apo AI) and Apolipoprotein AII (Apo AII)   
Apolipoprotein AI (Apo AI) is Apo AI is the major protein found in HDL 
(Julve et al., 2016). Also, chylomicrons assembled and secreted from the intestine have 
been found to be composed of considerable quantities of apo AI (Julve et al., 2016). 
Apo AI is first synthesized by the ER and is later carried to the Golgi apparatus in the 
form of vesicles for modification where apo AI is added to the mature chylomicron 
particles before its release from the cells (Julve et al., 2016).  
On the other hand, Apolipoprotein AII (Apo AII) is a produced by the liver, 
has a molecular mass of 17,400 Da and has a homodimer structure made up of 77 
amino acids (Dominiczak & Caslake, 2011). It makes up approximately 20% of the 
total HDL pool (Dominiczak & Caslake, 2011).  
In summary, there are many types of lipoprotein with variable composition, 
size and function and some of their properties are listed in Table 1.1. 
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Table 1.1: List of different types of lipoproteins, structural composition and their 
constituents. Adapted from Goldstein (2001).  
 
Lipoprotein 
particle  
Size (Å) Density  C 
% 
TG 
% 
PL 
% 
ApoP 
% 
Apolipopro-
tein 
Chylomicrons  800-5000 0.95 3 90 5 9 AI, AII, B, 
CI, CII, CIII 
VLDL 300-800     0.95-
1.006 
10 70 10 10 BI, CI, CII, 
CIII, E 
IDL 250-350  1.006-
1.019 
- - - - B, CIII, E 
LDL 180-280      1.019-
1.063 
26 10 15 25 B 
HDL 50-120      1.063-
1.210 
20 5 25 50 AI, All 
Table 1.1 abbreviations: C: cholesterol, TG: triglycerides, PL: phospholipids, ApoP: apopro-
tein 
1.4 Low density lipoprotein receptor (LDLR): structure and function  
Low density lipoprotein receptor (LDLR) is embedded in the cell membrane 
and it functions in the clearance of LDL containing cholesterol particles (Go & Mani, 
2012). The LDLR also plays a role in maintaining cholesterol homeostasis as well as 
lipid and lipoprotein metabolism in mammals. LDLR is a cell membrane glycoprotein 
that functions in the binding and internalizing of circulating cholesterol-containing lip-
oprotein particles. LDLR is ubiquitously expressed and is a key receptor for maintain-
ing cholesterol homeostasis in mammals (Go & Mani, 2012). It is first synthesized as 
an immature and inactive ER precursor glycoprotein of 120 kDa containing the core 
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sugar (Nacetylgalactosamine) of the O-linked chains and high-mannose N-linked car-
bohydrate chains and is translocated to the Golgi complex where it gets further glyco-
sylated into the mature form with 160 kDa molecular weight (Ashavaid et al., 2000). 
As discussed earlier, LDL particle is composed of an extremely important protein 
apoB100 which is essential for the recognition of LDL by LDLR. The mature form of 
LDLR located in the cell plasma membrane identifies the circulating LDL particle and 
internalizes as shown in Figure 1.6 through endocytosis in the form of clathrin coated 
pits (Go & Mani, 2012). LDLR adaptor protein 1 (LDLRAP1) and disabled homolog 
2 (Dab2) mediate the clustering of the LDL- LDLR complex into clatherin-coated pits 
by interacting with the cytoplasmic tail of LDLR. Once the ligand-receptor complex 
is internalized into the cell, clatherin detaches and vesicles fuse into the endosomes 
where LDL- LDLR dissociate due to the difference in pH created by ATP driven pro-
ton pumps (Go & Mani, 2012). Once the ligand-receptor complex is dissociated, the 
LDL particles are transported to the lysosomes and are degraded by hydrolytic lysoso-
mal enzymes while LDLR is recycled back to the cell membrane in a vesicle alone to 
repeat the cycle (Go & Mani, 2012). LDLR has a 20-hour life span and it therefore can 
carry out multiple rounds of endocytosis (Brown & Goldstein, 1986). During LDL’s 
internalization into the cell, it stimulates three mechanisms: first, it decreases the ex-
pression of 3- hydroxyl-3-methylglutaryl-coA reductase enzyme which in turn causes 
a decrease in endogenous cholesterol synthesis (Go & Mani, 2012). Secondly, LDL 
increases the degradation of toxic unusable cholesterol through increasing acyl-coA 
cholesteryl acyl transferase (ACAT) activity. Lastly, LDL also inhibits the synthesis 
of LDLR to decrease the clearance of LDL through SREBPs (Go & Mani, 2012). 
Sterol regulatory element binding protein (SREBP) is essential for regulation of 
LDLR’s transcription (Zhang et al., 2016).  
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dapted A ynthesis, pathway and function.LDLR’s sFigure 1.6: Schematic diagram of 
. (2001) .Goldstein et alfrom  
LDLR is first transcribed and processed in the nucleus. (1) It is translocated from the nucleus as precursor LDLR 
120 kDa with a molecular weight of 120 KDa and is synthesized and folded in the ER into its immature form of 
n extensively glycosylated into the mature 160 kDa for in the Golgi molecular weight. (2) LDLR is the
apparatus. Mature form of LDLR is transported in a vesicle to the cell membrane where it can perform 
l through its function. (3) LDLR binds with LDL. (4) LDLR internalizes LDL molecules into the cel
DL complex and are L-oated vesicles start to form to contain the LDLRc-endocytosis and clatherin
LDL -then delivered to endosomes (5) Due to the acidic environment in the lysosomes, LDLR
d are hydrolyzed whereas the LDLR is complex dissociates. The LDL particles reach the lysosomes an
.recycled back to the cell membrane for another cycle 
 
1.4.1 LDLR structure  
LDLR is a transmembrane receptor glycoprotein encoded by the gene LDLR. 
According to Uniprot (Bateman, 2019), LDLR possess a molecular mass of 95,376 Da  
and is made up of 18 exons, spans 45 kb on the short arm of chromosome19p13.2 and 
is made up of 2583 nucleotides which are transcribed and translated into 861 amino 
acids including a signal sequence of 21 amino acids that is cleaved during translocation 
16 
of LDLR to the ER for modification (Go & Mani, 2012). The mature form of LDLR 
is composed of five distinct domains (Figure 1.7) as the following: 
Figure 1.7: Schematic diagram of LDLR domain structure and the corresponding ex-
ons in its gene. It demonstrates five distinct domains that compose the structure of a 
mature LDLR. Adapted from Goldstein et al. (2001).  
1) First domain is the LDLR binding domain (LBD) located on the N-terminal
end of the receptor and is made up of 292 amino acids (Südhof et al., 1985).
It provides stability for LDLR and plays a crucial role in the recognition of
LDL to LDLR through the interaction of short negatively charged amino
acids (Ser-Asp-Glu) in LBD binding with positively charged residues of
apoE and apoB in the LDL particle (Uribe et al., 2018). It is composed of
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seven repeats (LR1-LR7) indicated as each containing 40 residues (Uribe 
et al., 2018). There are six cysteine residues per repeat in the LDLR binding 
domain and they are all held together by disulphide bonds. Exons 2, 3, 5 
and 6 encode for repeats 1, 3, 6, and 6 respectively while the rest of the 
repeats are encoded by exon 4 (Südhof et al., 1985).  
2) EGF precursor domain is the second domain in the LDLR which is encoded 
by exons 7 to 14 and is comprised of 400 amino acids (Südhof et al., 1985). 
EGF domain is involved in the release of the LDL- LDLR complex in the 
endosome due to pH change. The EGF precursor domain is composed of 
three repetitive 40 amino acids repeats including EGF A, EGF B and EGF 
C (Südhof et al., 1985). EGF A mainly reacts with proprotein convertase 
subtilisin/kexin type 9 (PCSK9). PCSK9 plays a role in regulating LDLR’s 
homeostasis (Varret & Rabes, 2012). It binds to LDLR on the surface of 
the cell membrane and degrades them (Varret & Rabes, 2012). It has been 
implicated that gain of function mutations can cause a decrease in LDLR 
quantities due to an increase in affinity between PCSK9 and LDLR hence 
degrading more LDLR and leading to an increase in levels of LDL in the 
blood (Varret & Rabes, 2012). Gain of function mutations cause a meta-
bolic disorder called autosomal dominant hypercholesterolemia. However, 
loss of function of PCSK9 causes a reduction in affinity between PCSK9 
and LDLR hence, causing decreased levels of LDL in the blood (Varret & 
Rabes, 2012). Furthermore, the first two repeats (EGF A and EGF B) are 
separated from the third repeat (EGF C) by a multiple sequence of 280 
amino acids each 40 -60 amino acid sequences is separated by a conserved 
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motif (YWTD) referred to as the β-propeller region (Varret & Rabes, 
2012).  
3) O- linked sugars domain is the third domain encoded by exon 15 and plays 
a major role in the post translational modification of LDLR (Varret & 
Rabes, 2012). They are enriched with serine and threonine residues which 
serve as attachment of O-linked sugar chains and allows LDLR to expand 
into the extracellular space (Gent & Braakman, 2004).  Due to the differ-
ences in acidity in the cellular compartments, glycosylation helps in pre-
venting denaturation and stability of the immature LDLR during its trans-
location to different organelles in the cell (Gent & Braakman, 2004). Also, 
it can possibly prevent LDLR’s proteolytic cleavage by metalloproteases 
(Gent & Braakman, 2004).  
4) Domain four is referred to as the membrane-anchoring domain or the trans-
membrane domain. It keeps the LDLR fully attached to the cell membrane 
by serving as an attachment site (Varret & Rabes, 2012). This domain con-
stitutes 22 hydrophobic amino acids and is coded by exon 16 and the 5’ end 
of exon 17 (Varret & Rabes, 2012).  
5) Exons 17 and 18 codify for the cytoplasmic tail which mediates Endocyto-
sis of LDLR-LDL complex. The cytoplasmic tail is 50 amino acids long 
(Varret & Rabes, 2012). 
1.5 Mutations in LDLR are a major cause of Familial Hypercholesterolemia 
Familial Hypercholesterolemia (FH) is an inherited metabolic disorder of de-
fected lipoprotein metabolism and behaves in an autosomal dominant manner. FH oc-
curs due to mutations mainly in the LDLR gene which causes a decrease in cholesterol 
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catabolism (Benito-vicente et al., 2018). Worldwide, there are more than 90% reported 
mutations and cases in FH are caused by defected LDLR (Austin et al., 2004).  
FH can also be autosomal recessive as well and it is caused by mutations in 
genes other than LDLR such as PCSK9, apoB both constituting between 1% and 5% 
of mutations. PCSK9 variants are divided into two: (1) gain of function which means 
the recycling pathway of LDLR is disrupted leading to rapid degradation of LDLR by 
lysosomes reducing the numbers of LDLR on the cell membrane hence, LDL levels 
elevated. (2) loss of function which means more degradation of LDL. Mutations in 
apoB can cause impaired affinity between LDL and LDL hence, LDLR won’t be able 
to identify LDL molecules. Lastly, low density lipoprotein receptor adaptor protein 1 
(LDLRAP1) make up less than 1% of mutations and it causes autosomal recessive 
familial hypercholesterolemia (ARH) (Benito-vicente et al., 2018). ARH is milder in 
severity and has less visible phenotype than autosomal dominant familial hypercho-
lesterolemia (ADH). Clinically, FH is characterized by the appearance of skin lesions 
knows as tendons xanthomas (Figure 1.8), grey outline in the iris called corneal arcus 
(Figure 1.9), elevated levels of cholesterol in the blood and a history of premature 
coronary artery diseases (CAD). 
 
 
Figure 1.8: Tendon Xanthomas. Adapted from Harada-Shiba et al. (2018) 
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Figure 1.9: Corneal Arcus. Adapted from Harada- Shiba et al. (2018).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: The consequences caused by pathogenic LDLR mutants which lead to 
premature coronary artery disease known as atherosclerosis. Modified and adapted 
from Nordestgaard et al. (2013). 
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FH is a common genetic disease but often can be fatal if remained underdiag-
nosed. As mentioned, elevated levels of cholesterol can deposit on the walls of arteries 
and cause (CAD) such as atherosclerosis as represented in Figure 1.10. 
FH can occur in a homozygous manner and can occur in a heterozygous man-
ner. FH   homozygous (HoFH) patients have a higher exposure of CAD compared to 
FH heterozygous patients (HeFH). Previously, it has been reported that the prevalence 
of (HoFe) patients in people was 1: 106 people but recently, it has been reported that 
the prevalence is 1: 300,000. On the other hand, (HeFH) patients have a higher preva-
lence between 1: 200 or 1:300 people (Benito-vicente et al., 2018). Worldwide, there 
are more than 90% reported mutations caused by defected LDLR (Austin et al., 2004).  
According to HGMD database (Stenson et al., 2014), there a total of 2286 var-
iants that have been reported for LDLR classified as pathogenic or non-pathogenic and 
range between point mutations, missense mutations, non-sense mutations, deletions, 
insertions or duplications.  
The LDLR FH-causing mutations have been classified into six functional clas-
ses as illustrated in Figure 1.11 and summarized here:  
1) Class I mutants are generated when LDLR is not being synthesized 
properly or no LDLR is being synthesized at all. No LDLR precursor 
is being generated or LDLR transcript doesn’t exit the nucleus 
(Ashavaid et al., 2000). There are few reasons why LDLR is not being 
synthesized. 1) it could be due to missense/ point mutations in the pro-
motor sequence of LDLR. 2) incorrect mRNA processing. Class 1 are 
indicated “Null alleles” (Ashavaid et al., 2000).  
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2) Class II are classified as “Transport-defective Alleles”: involves slow 
trafficking of the LDLR precursor to ER/ ER to Golgi apparatus or im-
proper folding and retention of LDLR in the ER (Ashavaid et al., 2000). 
Class II may happen due to a defect in manufacturing LDLR which 
resulted in a premature stop codon that lead to the synthesis of a trun-
cated LDLR (Ashavaid et al., 2000). Also, another possibility could be 
the absence of some cysteines in some cysteine binding domains and 
thus causes a complete retention in the ER stimulating ER stress and 
activating ERAD machinery (Ashavaid et al., 2000).  
3) Defective binding of LDL to LDLR is class III and are referred to as 
Binding-defective Alleles (Ashavaid et al., 2000). Despite its complete 
post translational modification, in this class, LDLR lacks the affinity to 
bind with LDL (Ashavaid et al., 2000).  
4) The fourth class of LDLR variants are endocytosis defective variants. 
Complete binding of LDLR to LDL but the cell’s incapable of taking 
up the complex into clatherin coated clusters (Ashavaid et al., 2000). It 
may be due to mutated or deleted domains in the LDLR structure par-
ticularly the transmembrane (4th) and cytoplasmic tail (5th) domains in 
LDLR (Ashavaid et al., 2000). 
5) Deletions in the EGF precursor domain are class V (Ashavaid et al., 
2000). The fifth class of LDLR mutants happens when there is a muta-
tion or a complete deletion of EGF precursor domain which results in 
complete internalization of LDL- LDLR complex but the dissociation 
of LDLR and LDL in endosomes fails to take place. Hence, LDLR gets 
degraded with the LDL in the lysosomes (Ashavaid et al., 2000). LDLR 
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in this class isn’t recycled back to the surface.  Class V are known as 
Recycling-deficient Alleles (Ashavaid et al., 2000).  
6) Class VI has been recently discovered and basically happens due to in-
complete attachment of mature LDLR in the cell membrane caused by 
mutations in the domain responsible for anchoring LDLR in the cell 
membrane which is the cytoplasmic tail (Ashavaid et al., 2000). 
 
Figure 1.11: Elucidates the different LDLR variant classes. Adapted from Hovingh et 
al. (2013). 
  
 
 The above listed LDLR mutant classes can cause a metabolic disorder known 
as Familial Hypercholesterolemia (FH) which inherited in an autosomal dominant 
manner (Südhof et al., 1985).  
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1.6 Cardiovascular disease and hypercholesterolemia in UAE 
Familial Hypercholesterolemia is a metabolic disorder than has been studied 
for the past decades. There are a total of 2286 variants causing FH reported by HGMD 
(Stenson et al., 2014) worldwide. The disease is still being studied and mutations are 
still being discovered. According to HGMD, most of those mutations are caused by 
LDLR gene. However, FH remains underdiagnosed and underestimated. Cascade 
screening is usually performed to identify FH patients through genetic testing and cho-
lesterol testing. Once an FH patient is identified, first degree relatives are screened and 
thereby expanding the number of cases to be studied and helps in the early diagnosis 
of FH (Dias & Peng, 2017).  However, there are some countries especially MENA 
region were cascade screening is unavailable which makes it difficult to identify FH 
cases and its molecular causes (Al-Mazrooei, 2008). Immigration is one of the causes 
of FH in North American and Western European countries due to Arab ancestry. In 
the MENA region, several mutations causing FH were discovered in Iraq, Algeria, 
Kuwait, Morocco, Palestine, Bahrain and Syria. However, FH was extensively studied 
in Arab countries such Lebanon, Tunisia and UAE. Amongst all Arab countries, in 
1995, UAE has been found to have the highest prevalence of FH as reported by M. 
Agrawal and his colleagues. One of the major causes contributing to FH in the MENA 
region is consanguineous marriages (Al-Mazrooei, 2008).  
Cardiovascular diseases such as coronary artery diseases cause a huge threat 
on Arab countries such as UAE being the highest cause of death in the country. In 
2004, it has been estimated that UAE’s population was around 4.3 million citizens (Al-
Mazrooei, 2008). Out of the 4.3million people in UAE, 3 million were expatriates. 
UAE is a developing and diverse country harboring many nationalities and ethnic 
backgrounds (Al-Mazrooei, 2008) . 50% are South Asians, 23% are Iranian and Arabs, 
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19% of them are Emiratis, and the rest 8% are East Asians and Westerners. Over the 
years, UAE has been rapidly evolving and changed into a more luxurious life. Due to 
this change and development, new diseases started to emerge due to the availability of 
unhealthy food and lack of exercise (Al-Mazrooei, 2008). In 2000, UAE has witnessed 
the highest morbidity and mortality rates. Cardiovascular diseases had the highest peak 
of morbidity and mortality in UAE having the highest death rate of 25.4%. The most 
important factors that contribute to cardiovascular diseases are genetics, hyper-
lipidemia and smoking. Basically, hyperlipidemia is an increase of lipids in the blood. 
Cholesterol blood levels and their severity are classified in Table 1.2.  
 
Table 1.2: Cholesterol blood levels and their clinical classifications in terms of  
severity.  
 
LDL levels (mg/dL) Classification  
>200 (>5.17 mmol/L) Mild hypercholesterolemia  
200-240 (5.17- 6.18 mmol/L) Moderate hypercholesterolemia  
>240 (>6.21 mmol/L) Severe hypercholesterolemia  
 
Although it is evident that CVDs are prevalent in UAE, but the underlying 
molecular causes are not well established. Therefore, this project has been initiated to 
elucidate the molecular and cellular basis of FH in among Emiratis in collaboration 
with Imperial College London Diabetes Center in Abu Dhabi Dr Hinda Daggag, Dr 
Maha Barakat and Groningen University in the Netherlands. Together, they have iden-
tified a list of LDLR missense variants in Emirati patients with suspected FH. The 
following are some of the variants they have identified: (p. Cys167Phe), (p. 
Asp178Asn), (p. Glu277Lys), (p. Gly314Arg), (p. His327Tyr), (p. Met652Thr) and (p. 
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Arg814Gln). Therefore, the aim of this MSc research project is to investigate the path-
ogenicity of some of the identified variants in the LDLR gene in Emirati patients with 
hypercholesterolemia and to delineate the cellular effects of the listed variants in 
LDLR which may potentially help in designing and developing new therapeutic strat-
egies.  
In this project, cellular models using mammalian constructs of wild type and 
mutant LDLR were generated to study the subcellular localization of the LDLR mu-
tants compared to the wild type as well as to study processing and post transitional 
modification of LDLR mutants and compare them wild type.  
The specific objectives of this project are: 
1) Generate the LDLR missense variants found in Emirati patients with suspected 
FH using site directed mutagenesis with a mammalian expression vector as 
template. 
2) Express the wild type and the generated LDLR variants in mammalian cells 
(HeLa and HEK2933). 
3) Establish the subcellular localization of the mutant proteins relevant to wild 
type using confocal fluorescence microscopy.  
4) Evaluate the glycosylation profiles of the mutants and compare them to wild 
type. 
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Chapter 2: Methods 
 
2.1 Antibodies  
The antibodies with their dilutions and sources were as follows: antibodies for 
immunofluorescence: mouse monoclonal anti-HA-tag [1:200; Cell Signaling Technol-
ogies (CST; Danvers, MA, USA)], rabbit polyclonal anti-calnexin (CANX, 1: 200; 
Santa Cruz Biotechnology, Dallas, TX, USA), Alexa Fluor 568-goat anti-mouse IgG 
(1: 200; Molecular Probes, Eugene, OR, USA) and Alexa Fluor 488-goat anti mouse 
IgG (1:200, Molecular Probes). For western blotting, the antibodies and their dilutions 
are as follows: mouse monoclonal anti-HA-tag [1:1000; Cell Signaling Technologies 
(CST; Danvers, MA, USA)], anti-mouse monoclonal antibody [1: 40,000; Cell Sig-
naling Technologies (CST; Danvers, MA, USA)]. As a loading control for western 
blot, the following antibodies were used: anti β- actin [1: 1000; Cell Signaling Tech-
nologies (CST; Danvers, MA, USA)], Anti-mouse [1: 40,000; Cell Signaling Technol-
ogies (CST; Danvers, MA, USA)].  
2.2 Generation of E. coli competent cells 
The purpose of generating E.coli competent cells is to introduce foreign DNA 
or plasmid into a host cell for plasmid amplification (Chang et al., 2017). JEM109 E. 
coli cells were generated following Chang et al (2017) protocol.  
2.3 Generation of expression mutant constructs using site directed mutagenesis  
Mutagenic primers for the selected mutants were designed using Primer X. 
pC3-LDLR HA tagged plasmid was kindly provided by Dr. Allaf from Imperial Col-
lege London. Through sequential site directed mutagenesis, the HA epitope tag was 
introduced at the C-terminus of the pC3-LDLR sequence (Kizhakkedath et al., 2019). 
According to (Kizhakkedath et al., 2019), two sets of primers listed in Table 2.1 were 
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designed and used by Dr. Allaf to introduce the HA tag into the pC3-LDLR sequence. 
A set for the first five amino acid codons and another primer set for introducing the 
remaining four amino acid codons of the HA tag.  
 
Table 2.1: List of primers used for insertion of C-terminal HA-tag (Kizhakkedath et 
al., 2019) and for SDM.  
 
First five amino acid codons in the 
HA tag 
F: GAG GAT GAC GTG GCG TAC CCA TAC 
GAT GTT TGA ACA TCT GCC TGG 
R: CCA GGC AGA TGT TCA AAC ATC GTA 
TGG GTA CGC CAC GTC ATC CTC 
Remaining four amino acid codons 
in the HA tag.  
F: GTA CCC ATA CGA TGT TCC AGA TTA 
CGC TTG AAC ATC TGC CTG  
R: CCA GGC AGA TGT TCA AGC GTA ATC 
TGG AAC ATC GTA TGG GTA C 
F: Forward primer. R: Reverse primer. 
 
Table 2.2: LDLR variants along with their mutagenic primers.  
 
LDLR mutation  Mutagenic primers  
p. Cys167Phe  F: 5'CAGCTGTGGGCCTTCGACAACGACCC 3' 
R: 5' GGGTCGTTGTCGAAGGCCCACAGCTG 3' 
p. Asp178Asn  F: 5' GAAGATGGCTCGAATGAGTGGCCGC 3'  
R: 5' GCGGCCACTCATTCGAGCCATCTTC 3' 
p. Glu277Lys F: 5'GTTAATGTGACACTCTGCAAGGGACCCAACAAGTTC 3' 
R: 5’GAACTTGTTGGGTCCCTTGCAGAGTGTCACATTAAC 3' 
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Table 2.2: LDLR variants along with their mutagenic primers (Continued).  
 
LDLR mutation  Mutagenic primers  
p. His327Tyr F: 5' GGCGGCTGTTCCTACGTCTGCAATG 3'  
R: 5' CATTGCAGACGTAGGAACAGCCGCC 3' 
p. Met652Thr F: 5' CCCCAGAGGATACGGTTCTCTTCCAC 3'  
R: 5' GTGGAAGAGAACCGTATCCTCTGGGG 3' 
p. Arg814Gln F: 5' CTATGGAAGAACTGGCAGCTTAAGAACATCAAC 3' 
R: 5' GTTGATGTTCTTAAGCTGCCAGTTCTTCCATAG 3' 
F: Forward primer. R: Reverse primer 
 
Site directed mutagenesis was carried out using Pfu Ultra HF polymerase and 
the list of primers in Table 2.2 and under the conditions in (Figure 2.1) (Stratagene, La 
Jolla, CA, USA).  
 
 
 
 
 
Figure 2.1: Schematic diagram of PCR conditions for site-directed mutagenesis.  
 
 
PCR samples were digested with Dpn1 enzyme (Invitrogen) at 37˚C for 4 hours 
to eliminate methylated DNA at 37˚C for 4 hours. Transformation was carried out to 
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introduce mutants’ DNA into JM109 E. Coli strain to amplify mutated plasmids. Com-
petent cells and dpn1 digested samples were cultured on LB agar (Invitrogen) plates 
and were left to grow overnight. After overnight growth, inoculation was performed 
and colonies were picked and grown in LB broth overnight. DNA extraction was done 
following Qiagen’s miniprep kit protocol and finally the DNA concentration was 
measured using NanodropTM 2000/2000c spectrophotometers (Thermofisher).  
2.4 Confirmation of the mutagenesis using Sanger DNA sequencing 
Generation of LDLR variants was confirmed through Sanger DNA sequencing. 
Sequencing was performed using the dideoxy Sanger method by fluorescent automated 
sequencing on the ABI 3130xl genetic analyzer (Applied Biosystems, Waltham, MA, 
USA).  
2.5 Cell culture and transfection using FuGene HD  
In this project two immortalized and adherent cell lines were used. HeLa cells 
which are cervical cancer cells and Hek293T cells (HEK-293T; ATCC, Manassas, VA, 
USA) which are kidney cancer cells. Both cell lines have a similar cell culture protocol 
but are used for different purposes.  Prior to starting any experiments, everything in-
cluding Dulbecco’s modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA, 
USA) supplied with 10% Fetal Bovine Serum (FBS; invitrogen) and 100 U.ml-1 peni-
cillin/streptomycin at 37°C with 5% CO2. For immunostaining and western blot, HeLa 
cells and Hek293T were cultured and maintained. T25 flask (Invitrogen) was used to 
maintain both cell lines. The ideal cells confluency is 70% to start with experiments.  
70% confluent cells were split by aspirating DMEM using a 5 ml electronic flask. PBS 
was used to wash DMEM residue and then cells were trypsinized using Trypsin for 5 
minutes at 37˚C in a sterile cell culture incubator. 5 ml DMEM was added to stop the 
action of Trypsin and cells were passaged to a new flask containing fresh DMEM.  
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2.6 Immunocytochemistry and confocal microscopy and imaging  
For immunostaining, coverslips were sterilized using 70% ethanol, absolute 
ethanol and UV light. Afterwards, sterilized coverslips were divided into correspond-
ing wells in the 24- well tissue culture plate. 1 ml of HeLa cells were added into each 
well containing coverslip and were left to grow for 24 hours. To study the localization 
of LDLR, transient transfection was done. 1 ml eppindorf tube for each well was used 
to mix 26 µL of Opt i-MEM media (Thermofisher) , 1.5 µL FuGene HD trans-
fect ion reagent (Promega, Madison, WI, USA) and 1 µg of HA- tagged wildtype 
LDLR wildtype or mutant constructs (Kizhakkedath et al., 2014). GFP-HRas plasmid 
was used as a plasma membrane marker and cotransfected with HA-tagged wild-type 
or mutant plasmids (Ali et al., 2010). Twenty-four hours after transfection, HeLa cells 
that were grown on cover slips in a 24 – tissue culture well plate were washed with 
PBS trice, fixed with -20˚C ice cold methanol (Fisher Chemical) for 5 minutes at -
20˚C. After that, the fixed cells were washed again with PBS to remove any methanol 
residue and then blocking was done using 1% Bovine Serum Albumin (BSA) (Pierce 
TM) two hours at room temperature. After two hours of blocking, HeLa cells were in-
cubated with primary antibodies for 45 minutes at room temperature in mouse mono-
clonal anti-HA-tag [1: 200; Cell Signaling Technologies (CST; Danvers, MA, USA)] 
and rabbit polyclonal anti-calnexin (CANX, 1: 200; Santa Cruz Biotechnology, Dallas, 
TX, USA) Afterwards, cells were washed with PBS and incubate with Alexa Fluor 
568-goat anti-mouse IgG (1: 200; Molecular Probes, Eugene, OR, USA) and Alexa 
Fluor 488-goat anti mouse IgG (1:200, Molecular Probes) secondary antibodies for 45 
minutes at room temperature. Finally, cells were mounted on cover slides using (ICN 
biomedicals) immunofluor mounting medium. Confocal microscopy and imaging was 
performed using Nikon Eclipse system (Nikon instruments Inc) containing FITC and 
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TRITC filters. Images were made using 100x oil immersion objective lens, adjusted 
and merged using Image J software. All images presented are single sections in the z-
plane.  
2.7 Western blot analysis for glycosylation profile analysis  
Cell culture and transfection using FuGene HD 
For Western blot, Human embryonic kidney cells (Hek293T) were used. In a 
6- tissue culture well plate, transfection was performed using FuGene HD (Promega) 
and using 1ug of wild type LDLR plasmid DNA or mutant plasmids. After 48 hours 
of transfection, HEK293T cells were washed with PBS, harvested using cell scrappers 
(Fisherbrand TM) , collected into Eppendorf tubes and spun using a table centrifuge for 
5 minutes at 500 g at 4C. Supernatant containing cell debris was discarded and the 
pellet was washed with 800 µL cold PBS and centrifuged again for 5 minutes at 500 g 
at 4˚C. The supernatant containing all our protein was taken and stored at -20˚C.  
 
Quantification of protein concentration 
Protein estimation was performed using Bicinchoninic Acid Protein Assay 
(BCA kit, Pierce). According to BCA kit instructions, 2 mg/ml of stock BSA was pre-
pared and standard dilutions of BSA and RIPA buffer (Thermoscientific TM) were pre-
pared as listed in Table 2.3.  
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Table 2.3: Standard dilutions and protein dilutions.  
 
BSA (mg/ml)  BSA (2 mg/ml)  RIPA buffer (µL) 
2.0 50 0.0 
1.5 37.5 12.5 
1.0 25 25.0 
0.75 18.8 31.3 
0.50 12.5 37.5 
0.25 6.3 43.5 
0.125 3.1 46.9 
0.0 0.0 50.0 
 
Table 2.3 abbreviations: BSA: Bovine Serum Albumin.  
 
After preparing the standards, protein was diluted 5 times with RIPA buffer. 
Standard dilution duplicates and protein dilution duplicates were added into designated 
wells. 180 µL of mixture A + B were added per well and incubated at 37˚C for 1 hour. 
After incubation, the absorbance’s were measured at 562 nm through Tecan Infinite 
M200 Pro Microplate reader. The absorbance’s average values were used to draw a 
scatter plot along with a trend line equation. Through the trend line equation, the pro-
tein concentration was calculated and then multiplied by 5 since it was diluted 5 times 
with RIPA buffer. Protein concentration was set at 20 µg. Based on the numbers on 
the Excel sheet, the calculations were done and protein samples were prepared. Sam-
ples were boiled at 95˚C in a hot well plate for 5 minutes.  
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Western blot analysis 
After identifying volumes for each mutation, protein was prepared and mixed 
well in a cocktail of 5x Lamelli buffer and RIPA buffer. HA-tagged proteins were run 
in an 8% acrylamide gel (ThermoFisher) at 90 V which was gradually increased to 120 
V. Transfer was done for an hour at room temperature at 60 V using PVDF membrane 
(Immobolin). The membrane was washed thrice with TBST each time for 6 minutes 
and incubated with respective antibodies. Primary antibody mouse monoclonal anti-
HA-tag [1:1000; Cell Signaling Technologies (CST; Danvers, MA, USA)] incubation 
was done overnight. Secondary antibody anti-mouse monoclonal antibody [1: 40,000; 
Cell Signaling Technologies (CST; Danvers, MA, USA)]. PVDF membrane was in-
cubated 1 ml of ECL plus for 5 minutes (ECL plus kit; ThermoFisher TM). Detection 
and development was done using Typhoon FLA 9500 imager. B-actin was used as a 
loading control, PVDF membrane was incubated with primary antibody anti- β- actin 
[1: 1000; Cell Signaling Technologies (CST; Danvers, MA, USA)]. PVDF membrane 
was washed trice with TBST each time for 6 minutes then incubated with secondary 
antibody anti-mouse monoclonal antibody [1: 40,000; Cell Signaling Technologies 
(CST; Danvers, MA, USA)]. PVDF membrane was incubated 1 ml of ECL plus for 5 
minutes (ECL plus kit; ThermoFisher TM). Finally, development was done using Ty-
phoon FLA 9500 imager. Images were edited on ImageJ software.  
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Chapter 3: Results 
 
The list of the studied missense mutants is shown in Table 3.1 and they were 
identified by our collaborators at Imperial College London Diabetes Center in Abu 
Dhabi. According to HGMD (Stenson et al., 2014) and LOVD (Fokkema et al., 2011), 
(p. Cys167Phe) is the only novel variant. However, they have been all classified as 
potentially “disease causing” but further evidence was needed. 
 
Table 3.1: List of LDLR missense mutants studied for the purpose of this thesis.  
 
Coding position Protein position  
c. 500G>T p. Cys167Phe 
c. 532G>A p. Asp178Asn 
c. 829G>A p. Glu277Lys 
c. 940G>A p. Gly314Arg 
c. 979C>T p. His327Tyr 
c. 1956 G>C p. Met652Thr 
c. 2441 G>A p. Arg814Gln 
  
3.1 All mutants were generated and sequenced  
Site directed mutagenesis was performed to generate the desired mutants using 
pC3- LDLR HA tagged wild type plasmid as template (Kizhakkedath et al., 2019). The 
template plasmid has kindly been provided by Dr. F. Allaf from Imperial College Lon-
don. The LDLR missense mutations: (p. Cys167Phe), (p. Asp178Asn), (p. 
Glu277Lys), (p. Gly314Arg), (p. His327Tyr), (p. Met652Thr) (p. Arg814Gln) were 
successfully generated through site directed mutagenesis using the list of primers in 
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Table 2.1.  
Sanger DNA sequencing was performed to confirm the successful generation 
of the desired mutants. The sequencing chromatograms and protein sequence align-
ments using Clustal Omega of all the generated mutants are shown in Figures (3.1-
3.7).  
 
 
 
 
Figure 3.1: Sequence chromatogram and alignment of mutant c.500 G>T; p. 
Cys167Phe. 
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Figure 3.2: Sequence chromatogram and alignment of mutant c.532 G>A; p. 
Asp178Asn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Sequence chromatogram and alignment of mutant c.829 G>A; p. 
Glu277Lys.  
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Figure 3.4: Sequence chromatogram and alignment of mutant c.940G>A; p. 
Gly314Arg.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Sequence chromatogram and alignment of mutant c.979 C>T; p. 
His327Tyr.  
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Figure 3.6: Sequence chromatogram and alignment of mutant c.1956T>C; p. 
Met652Thr.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Sequence chromatogram and alignment of mutant c.2441G>A; p. 
Arg814Gln.  
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3.2 The missense mutations (p. Cys167Phe), (p. Asp178Asn), (p. His327Tyr) and 
(p. Met652Thr) seem to affect the trafficking and cell surface expression of 
LDLR 
After successfully generating mutated LDLR constructs through site directed 
mutagenesis, immunocytochemistry was performed to investigate the expression and 
subcellular localization of the seven generated LDLR constructs at the cellular level. 
HeLa cells were co-transfected with EGFP-Ras plasmid which been used previously 
in the laboratory as a plasma membrane marker (Kizhakkedath et al., 2019) along with 
the wild type or the seven LDLR mutants individually. As predicted, the wild-type 
LDLR receptor was found to be localized to the plasma membrane as confirmed by its 
co-localization with GFP-H-Ras (Figure 3.8, panels A(iii)). On the other hand, out of 
the seven LDLR variants tested, (p. Glu277Lys), (p. Gly314Arg) and (p. Arg814Gln) 
were found to have a similar localization to the wild-type and were found to be exclu-
sively localized to the plasma membrane and were confirmed by their co-localization 
with the EGFP- HRas as displayed in (Figure 3.8 panels D (iii), E (iii) and H (iii)) 
respectively. Also, it was further confirmed that (p. Glu277Lys), (p. Gly314Arg) and 
(p. Arg814Gln) failed to co-localize with Calnexin which is an endogenous protein 
expressed exclusively in the ER and therefore has been used as an ER marker confirm-
ing that (p. Glu277Lys), (p. Gly314Arg) and (p. Arg814Gln) are plasma membrane 
retained in (Figure 3.9 panels D (iii), E (iii) and H (iii)) respectively.  
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Figure 3.8: Hela cells were grown on sterile coverslips for 24 hours and transiently 
co transfected with HA-tagged LDLR plasmids and GFP tagged HRAS plasmid us-
ing FuGene transfection reagent and stained with anti-HA antibodies. 
The first horizontal panel (i) illustrates the fluorescent staining and expression of HA-tagged LDLR 
(ii) shows Hela cells expressing the GFP-HRas fluorescent signal (iii) shows the merged images of (i) 
and (ii) illustrating the co-localization of HA tagged LDLR and GFP HRas. GFP HRas was used as a 
plasma membrane marker. Images were captured via Nikon confocal microscopy at 100x and merged 
through Image J software. 
42 
 
 
 
 
 
 
 
Figure 3.8: Hela cells were grown on sterile coverslips for 24 hours and transiently 
co-transfected with HA-tagged LDLR plasmids and GFP tagged HRAS plasmid us-
ing FuGene transfection reagent and stained with anti-HA antibodies (Continued). 
The first horizontal panel (i) illustrates the fluorescent staining and expression of HA-tagged LDLR 
(ii) shows Hela cells expressing the GFP-HRas fluorescent signal (iii) shows the merged images of (i) 
and (ii) illustrating the co-localization of HA tagged LDLR and GFP HRas. GFP HRas was used as a 
plasma membrane marker. Images were captured via Nikon confocal microscopy at 100x and merged 
through Image J software. 
 
Furthermore, the other FH-associated LDLR mutants (p. Cys167Phe), (p. 
Asp178Asn), (p. His327Tyr) and (p. Met652Thr) were found to be localized intracel-
lularly as seen in (Figure 3.9 panels B (iii), C (iii), F (iii) and G (iii)) respectively. The 
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intracellular localization of those mutants was confirmed through there co-localization 
with Calnexin. None of those mutants showed any significant co-localization with the 
EGFP-HRas as apparent in (Figure 3.8 panels B (iii), C (iii), F (iii) and G (iii)). 
 
 
Figure 3.9: Hela cells were grown on sterile coverslips for 24 hours and transiently 
transfected with HA-tagged LDLR plasmids using FuGene transfection reagent and 
stained with anti-HA antibodies and anti- Calnexin (Calx) antibodies. 
The first vertical panel (i) shows the fluorescent staining of HA-tagged LDLR (ii) shows the fluores-
cent staining of Calnexin (Calx) in HeLa cells (iii) shows the merged images of (i) and (ii) illustrating 
the co-localization of HA tagged LDLR with the Calnexin (Calx) used as the ER marker. Images were 
captured through Nikon confocal microscopy at 100x and merged through Image J software. 
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Figure 3.9: Hela cells were grown on sterile coverslips for 24 hours and transiently 
transfected with HA-tagged LDLR plasmids using FuGene transfection reagent and 
stained with anti-HA antibodies and anti- Calnexin (Calx) antibodies (Continued). 
The first vertical panel (i) shows the fluorescent staining of HA-tagged LDLR (ii) shows the fluores-
cent staining of Calnexin (Calx) in HeLa cells (iii) shows the merged images of (i) and (ii) illustrating 
the co-localization of HA tagged LDLR with the Calnexin (Calx) used as the ER marker. Images were 
captured through Nikon confocal microscopy at 100x and merged through Image J software. 
3.3 FH associated LDLR mutants have preserved glycosylation profiles 
 The LDLR mutants were subjected for western blot to study their glycosylation 
profiles.  As mentioned in the introduction, mature LDLR is glycosylated in the ER 
and consists of O-linked and N-linked glycosylation. A mature LDLR will present to 
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migrating bands in an immunoblot. A slow migrating 160 kDa band and a slower mi-
grating 120 kDa band. 160 kDa represents mature LDLR and 120 kDa represents pre-
cursor LDLR. Using an anti-HA tag, we were able to observe migrating LDLR in 
western blot (Figure 3.10). Evidently, wild-type LDLR displayed two migrating bands, 
mature LDLR and precursor LDLR. The negative control showed no bands which is 
considered as a good sign indicating there were no non-specific binding of antibodies. 
(p. Asp482His) is an ER retained LDLR mutant that was previously studied by (Ki-
zhakkedath et al., 2019). (p. Asp482His) used here as a positive control. LDLR mu-
tants (p. Cys167Phe), (p. Asp178Asn), (p. Glu277Lys), (p. Gly314Arg), (p. 
His327Tyr), (p. Met652Thr) and (p. Arg814Gln) all displayed two migrating bands. 
However, (p. Cys167Phe) and (p. Met652Thr) bands appeared faint.  
 
 
 
 
Figure 3.10: Western blot results of the wildtype, (-) control (Untransfected), p. 
Asp482His (+) control, (p. Cys167Phe), (p. Asp178Asn), (p. Glu277Lys), (p. 
Gly314Arg), (p. His327Tyr), (p. Met652Thr), (p. Arg814Gln).  
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Chapter 4: Discussion 
 
FH is an inherited form of FH affecting 1 in 250 and often is caused by variants 
(mutation) in the LDLR gene. Hypercholesterolemia is highly prevalent in the UAE 
affecting about 25% of the Emirati population. Often this condition runs in Emirati 
families suggesting an inherited aspect but the underlying cause have not been yet 
identified. LDLR variants were identified by Imperial College in Emiratis with sus-
pected FH. The identified variants affect the various known LDLR domains (Figure 
4.1). Therefore, in this thesis, the impact of seven of those variants on the cellular 
behavior of the receptor were evaluated. 
 
 
 
 
Figure 4.1: Schematic diagram of the five structural domains and the location of the 
studied LDLR variants. Adapted and modified from Rodríguez-Jiménez et al. (2019). 
 
Some of the generated LDLR genetic variants have been reported to cause fa-
milial hypercholesterolemia (FH). Among those variants (Figure 4.1), two of them are 
located at exon 4 in the ligand binding domain of the LDLR (p. Cys167Phe) and (p. 
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Asp178Asn). Also, another two variants (p. Glu277Lys) and (p. Gly314Arg) were 
found to be located at exon 6 in the ligand binding domain of the LDLR. The rest of 
the mutants (p. His327Tyr), (p. Met652Thr) and (p. Arg814Gln) were found to be lo-
cated at exons 7, exon 13 and exon 17, respectively.  
It has been reported that (p. Cys167Phe) is a novel mutation but (p. 
Asp178Asn) has been reported before by HGMD (Stenson et al., 2014) and LOVD 
(Fokkema et al., 2011). However, both variants have been reported as disease causing. 
The ligand binding domain (LBD) of the LDLR plays a role in the stability of the 
LDLR structure. The LBD consists of 40 residues with six conserved cysteine amino 
acids. At the C terminus of each LR, there are a group of negatively charged amino 
acids (Ser-Asp-Glu) that interact with positively charged amino acid residues on apoB 
and apoE. According to our results, both (p. Cys167Phe) and (p. Asp178Asn) were 
expressed on the plasma membrane and were expressed intracellularly. We predicted 
that a substitution in Cys to Phe at position 167 and a change in Asp to Asn at position 
178 cause altered LDL-LDLR binding capacity. However, (p. Asp178Asn) showed a 
high expression while (p. Cys167Phe) showed a low LDLR expression on the im-
munoblot. According to a mutational analysis done by (Esser et al., 1988), LR3- LR7 
are required for maximal binding of LDL and LDLR. Variants (p. Glu277Lys) and (p. 
Gly314Arg) are located at exon6 in the ligand binding domain in LDLR. Variant (p. 
Glu277Lys) was first reported and identified in Swedish children for the first time 
(Ekstrom, Abrahamson, Sveger, Lombardi, & Nilsson‐Ehle, 1995). The substitution 
of glutamic acid which is an acidic amino acid to Lysine which is a basic amino acid 
alters the protein folding of LDLR since Asp and Glu are negatively charged residues 
and are important in coordinating calcium ions and their interactions with cystienes 
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forming disulphide bridges (Uribe et al., 2018) (Rodríguez-Jiménez et al., 2019). Var-
iant p. Gly314Arg located at exon 6 and is caused by a change in the last nucleotide of 
exon 6 (G>A at 940). Glycine is present in the epidermal growth factor domain (EGF) 
and is located beside a threonine. However, according to (Usifo et al., 2012), they 
predicted that the binding affinity of calcium ion can be altered if glycine was substi-
tuted with an arginine and through there in-silico analysis and they discovered that this 
variant has no evidence of pathogenicity (Usifo et al., 2012). However, according to 
HGMD (Stenson et al., 2014) and LOVD (Fokkema et al., 2011), it was classified as 
“disease causing”. Moreover, variant (p. His327Tyr) affects the EGF-A domain. As 
mentioned in the introduction, EGF-A interacts with proprotein convertase subtil-
isin/kexin type 9 (PCSK9) which plays a role in regulating LDLR homeostasis. A mu-
tation in this domain can further induce PCSK9’s activity and lead to an increase 
LDLR catabolism (Jelassi et al., 2009). As illustrated through confocal images, some 
of it is found to be localized mainly in the cytoplasm where it gets degraded by PCSK9. 
Mutation (p. Met652Thr) is found in the β-propeller region made up of YWTD repeats 
separating EGF-A and EGF-B repeats from EGF-C repeat. The mutant has shown in-
tracellular retention in HeLa cells in the confocal images and was slightly expressed 
in the immunoblot. The EGF domain is implicated in the release of the LDL- LDLR 
complex in the endosome due to pH change. Lastly, mutation (p. Arg814Gln), located 
at exon 17 encoding for the intracellular cytoplasmic domain of the LDLR. The cyto-
plasmic domain is extremely important in the release of modified LDLR from the ER 
(Rodríguez-Jiménez et al., 2019). It showed co-localization with EGFP-HRas and 
showed high LDLR expression.  
Positive control (p. Asp482His) was previously studied by (Kizhakkedath et 
al., 2019). The substitution of Asp to His at position 482 caused retention in the ER 
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and affected the trafficking of LDLR to the cell surface. According to functional anal-
ysis and studies, ER retained mutants induce ER stress which activate unfolded protein 
response (UPR). The misfolded proteins become substrates for ER-associated degra-
dation (ERAD). When ERAD fails to degrade misfolded proteins and get inactivated, 
it induces unfolded protein response (UPR). In the ER, inositol- requiring enzyme acts 
as a stress sensor and is activated when there are increased levels of ER stress (Ki-
zhakkedath et al., 2019). When UPR is activated, it reduces ER stress by increasing 
expression of stress alleviating genes and catalyzes the splicing of the mRNA of the 
transcription factor X-box binding protein (XBP-1) (Kizhakkedath et al., 2019).  Fur-
ther studies are now needed to further analyze the effects of these mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
 
 
Chapter 5: Conclusion 
 
5.1 Summary 
To summarize, seven LDLR Emirati variants were generated and their expres-
sion and co-localization was studied suggesting partial retention in the ER for some of 
them. According to the results of transfected Hek293T on the immunoblot, evidently, 
the wild type showed the highest expression. Similarly, (p. Glu277Lys) and (p. 
His327Tyr) showed an almost similar expression to the wildtype. On the other hand, 
(p. Asp178Asn) and (p. Arg814Gln) showed an intermediate expression unlike (p. 
Cys167Phe) and (p. Met652Thr) who showed the weakest expression on the im-
munoblot.  
5.2 Future experiments 
Internalization assays must be run in the future to further elucidate and deter-
mine the functionality, the binding capacity and classification of those mutants. Triton 
X solubility assay and quantitative PCR (qPCR) could be done in the future to measure 
the expression of XBP-1 for LDLR mutants. Endoglycosidase H sensitivity assay 
could be performed to further study the glycosylation status of these mutants. Also, a 
number of chaperons found in the ER that are associated with LDLR could be used to 
further study ER retained mutant’s interactions and compare it to the wildtype using 
multiple ER resident chaperons CANX/calreticulin system and the GRP78/GRP94 
system. The identified LDLR mutants could be further investigated in other cell lines 
such as HepG2 cell lines which could be a better cellular model to study and present 
familial hypercholesterolemia and its phenotype since FH occurs in the liver. Another 
possible future experiment is to study LDLR mutants on LDLR knockout cell lines. 
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Knockout cell lines are generated through removing endogenous LDLR and substitut-
ing it with the exogenous mutated LDLR gene. In this way, knockout cell lines will 
help us know if the results obtained from experiments are from the exogenous LDLR 
mutated form.  
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